These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 38794209)

  • 1. NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders.
    Egunlusi AO; Joubert J
    Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases.
    Ladagu AD; Olopade FE; Adejare A; Olopade JO
    Pharmaceuticals (Basel); 2023 Oct; 16(11):. PubMed ID: 38004401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.
    Costa BM; Irvine MW; Fang G; Eaves RJ; Mayo-Martin MB; Laube B; Jane DE; Monaghan DT
    Neuropharmacology; 2012 Mar; 62(4):1730-6. PubMed ID: 22155206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold.
    Ritter N; Korff M; Markus A; Schepmann D; Seebohm G; Schreiber JA; Wünsch B
    Cell Physiol Biochem; 2021 Mar; 55(S3):1-13. PubMed ID: 33656308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons.
    Swanger SA; Vance KM; Acker TM; Zimmerman SS; DiRaddo JO; Myers SJ; Bundgaard C; Mosley CA; Summer SL; Menaldino DS; Jensen HS; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2018 Feb; 9(2):306-319. PubMed ID: 29043770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus.
    Swanger SA; Vance KM; Pare JF; Sotty F; Fog K; Smith Y; Traynelis SF
    J Neurosci; 2015 Dec; 35(48):15971-83. PubMed ID: 26631477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors.
    Mullier B; Wolff C; Sands ZA; Ghisdal P; Muglia P; Kaminski RM; André VM
    Neuropharmacology; 2017 Sep; 123():322-331. PubMed ID: 28533163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid.
    Irvine MW; Fang G; Sapkota K; Burnell ES; Volianskis A; Costa BM; Culley G; Collingridge GL; Monaghan DT; Jane DE
    Eur J Med Chem; 2019 Feb; 164():471-498. PubMed ID: 30622023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.
    Acker TM; Khatri A; Vance KM; Slabber C; Bacsa J; Snyder JP; Traynelis SF; Liotta DC
    J Med Chem; 2013 Aug; 56(16):6434-56. PubMed ID: 23909910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.
    Yi F; Bhattacharya S; Thompson CM; Traynelis SF; Hansen KB
    J Physiol; 2019 Nov; 597(22):5495-5514. PubMed ID: 31541561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.
    Lütnant I; Schepmann D; Wünsch B
    Eur J Med Chem; 2016 Jun; 116():136-146. PubMed ID: 27061977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA receptors control vagal afferent excitability in the nucleus of the solitary tract.
    Vance KM; Rogers RC; Hermann GE
    Brain Res; 2015 Jan; 1595():84-91. PubMed ID: 25446446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.
    McKay S; Griffiths NH; Butters PA; Thubron EB; Hardingham GE; Wyllie DJ
    Br J Pharmacol; 2012 Jun; 166(3):924-37. PubMed ID: 22022974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of
    Strong KL; Epplin MP; Ogden KK; Burger PB; Kaiser TM; Wilding TJ; Kusumoto H; Camp CR; Shaulsky G; Bhattacharya S; Perszyk RE; Menaldino DS; McDaniel MJ; Zhang J; Le P; Banke TG; Hansen KB; Huettner JE; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2021 Jan; 12(1):79-98. PubMed ID: 33326224
    [No Abstract]   [Full Text] [Related]  

  • 19. Chimeric Glutamate Receptor Subunits Reveal the Transmembrane Domain Is Sufficient for NMDA Receptor Pore Properties but Some Positive Allosteric Modulators Require Additional Domains.
    Wilding TJ; Lopez MN; Huettner JE
    J Neurosci; 2016 Aug; 36(34):8815-25. PubMed ID: 27559165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postsynaptic GluN2B-containing NMDA receptors contribute to long-term depression induction in medial vestibular nucleus neurons of juvenile rats.
    Li YH; Li Y; Zheng L; Wang J
    Neurosci Lett; 2020 Jan; 715():134674. PubMed ID: 31809803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.